

**This Page Is Inserted by IFW Operations
and is not a part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- **BLACK BORDERS**
- **TEXT CUT OFF AT TOP, BOTTOM OR SIDES**
- **FADED TEXT**
- **ILLEGIBLE TEXT**
- **SKEWED/SLANTED IMAGES**
- **COLORED PHOTOS**
- **BLACK OR VERY BLACK AND WHITE DARK PHOTOS**
- **GRAY SCALE DOCUMENTS**

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox. ✓**



02.10.03

PATENTS

TECH CENTER 1600/2900

FEB 12 2003

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)
 RICH)
Serial No: **10/059,521**)
Filed: **January 29, 2002**)
For: **HIGH-THROUGHPUT STEM CELL**)
 ASSAY OF HEMATOPOIETIC STEM AND)
 PROGENITOR CELL PROLIFERATION)

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicant hereby voluntarily discloses the items listed on the attached Form PTO-1449 to the Assistant Commissioner for Patents. Copies of items (M - NNN) are enclosed herewith.

Applicant further reserves the right to establish the patentability of the claimed invention over any of the listed information should they be applied as references, and/or to prove that some of the cited information may not be prior art, and/or to prove that some of the cited information may not be enabling for the teachings they purport to offer. This statement further should not be construed as a representation that an exhaustive search has been made, or that the information cited herewith is material, or that there does not exist information more material to the examination of the present Application. The Examiner is specifically requested not to rely solely on the information submitted herein. On the contrary, the Examiner is requested to conduct an independent and thorough review of the information, and to form independent opinions as to their significance.

02/11/2003 TLWU11 00000013 10059521

01 FC:1806

180.00 OP

It is respectfully requested that the Examiner initial and return copies of the enclosed PTO-1449 and to indicate in the official file wrapper of the above-identified patent application that each item of the cited information has been considered.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to account no. 09-0528.

Date: 1/6/2003

David J. Hayzer
David J. Hayzer, PhD, J.D.
Attorney for Applicant
Reg# 43,329

Womble Carlyle Sandridge & Rice, PLLC
P.O. Box 7037
Atlanta, GA 30357-0037
(404) 962-7529 (Telephone)
(404) 870-2413 (Facsimile)

Docket No.: **R103 1030.1**

Express Mail Certificate


I hereby certify that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" in an envelope addressed to: Box IDS, Assistant Commissioner for Patents, Washington, D.C. 20231 on

2-6-03

Express Mail No.: EL 759081989 US

Signature: Aquarius Fosh

ATLANTA 340758v1



RECEIVED
FEB 12 2003
TECH CENTER 1600/2900
Sheet 1 of 5

AForm PTO-1449 INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Attorney Docket No. R103 1030.1	Serial No. 10/059,521
	Applicant Rich, Ivan	
	Filing Date January 29, 2002	Group

U.S. PATENT DOCUMENTS

Examiner Initials	Item	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	A						
	B						
	C						
	D						
	E						
	F						
	G						

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	H							
	I							
	J							
	K							
	L							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

/	M	"Circannual Variations Of Circadian Periodicity In Murine Colony-Forming Cells"; Aardal, Nils-Petter, Experimental Hematology, 12:61-67 (1984)
/	N	"Circadian Variations in Mouse Bone Marrow"; Aardal, N.P. & Laerum, O.D., Experimental Hematology, Vol. 11, No. 9, pp. 792-801 (1983)
3	O	"Cyclic Hematopoiesis in Dogs: Studies of Erythroid Burst-forming Cells Confirm an Early Stem Cell Defect"; Abkowitz, Janis L., Holly, Richard D., Hammond, William P. IV, Experimental Hematology, 16:941-945 (1988)

RECEIVED

FEB 12 2003
Sheet 2 of 5

/	P 4	"Hematopoietic Effects of Benzene Inhalation Assessed by Long-term Bone Marrow Transplantation"; Abraham, Nadar G., Environmental Health Perspectives, Vol. 104, Supplement 6, pp. 1277-82 (1996)
/	Q 5	"Circadian cell cycle variations of erythro- and myelopoiesis in humans"; Abrahamsen, JF, Smaaland, R, Sothorn, RB, Laerum OD, European Journal of Haematology, Vol. 58, pp. 333-45 (1997)
/	R 6	"Circadian and seasonal variations of hematopoiesis in cord blood"; Baudoux, E., et al, Bone Marrow Transplantation, Supplement 1, S12, p. 22 (1998)
/	S 7	"Toxicity on Human Hemopoietic Progenitors of 2'-2'-Difluoro-2'Deoxyctidine (Gemcitabine)"; Botta, Marco, et al, Anticancer Research, Vol. 18, pp. 1037-42 (1998)
/	T 8	"Measurement of the ADP:ATP ratio in human leukaemic cell lines can be used as an indicator of cell viability, necrosis and apoptosis"; Bradbury, D.A., Simmons, T.D., Slater, K.J., Crouch, S.P.M., Journal of Immunological Methods 240, pp. 79-92 (2000)
/	U 9	"The Growth Of Mouse Bone Marrow Cells <i>In Vitro</i> "; Bradley, T.R., Metcalf, D, Aust. J. Experimental Biological Medical Science, 44, pp. 287-300 (1966)
/	V 10	"Cyclic oscillations of neutrophils, monocytes, and CD8-positive lymphocytes in a healthy subject"; Carulli, Giovanni, et al, Haematologica, Vol. 85(4), pp. 447-48 (2000)
/	W 11	"Azidothymidine and interferon- α in vitro effects on hemotopoiesis: Protective in vitro activity of IL-1 and GM-CSF"; Castello, G, et al, Experimental Hematology 23, pp. 1367-71 (1995)
/	X 12	"Hematotoxicity of 5-Fluorouracil-Leucovorin in a Setting of Adjuvant Chemotherapy"; Cerruti, Alessandro, et al, Anticancer Research 14, pp. 2163-66 (1994) → (65)?
/	Y 13	"Chemopreventive Agent Resveratrol, a Natural Product Derived From Grapes, Triggers CD95 Signaling-Dependent Apoptosis in Human Tumor Cells"; Clement, M., et al, Blood, Vol. 92, No. 3, pp. 996-1002 (1998)
/	Z 14	"Idarubicinol myelotoxicity: a comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicin"; Corsini, C., et al, British Journal of Cancer, 82(3), pp. 524-528 (2000)
/	AA 15	"The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity"; Crouch, S.P.M., et al, Journal of Immunological Methods, 160, pp. 81-88 (1993)
/	BB 16	"Experimental basis for increasing the therapeutic index of carboplatin in brain tumor therapy by pretreatment with WR compounds"; Dox, F., et al, Cancer Chemother Pharmacol, 28, pp. 308-310 (1991)
/	CC 17	"Benzene-Induced Hematotoxicity and Bone Marrow Compensation in B6C371 Mice"; Farris, Georgia M., et al, Fundamental and Applied Toxicology 36, pp. 119-29 (1997)
/	DD 18	"Hematotoxicity on human bone marrow- and umbilical cord blood-derived progenitor cells and in vitro therapeutic index of methoxymorpholinyldoxorubicin and its metabolites"; Ghielmini, M., et al, Cancer Chemother Pharmacol 42, pp. 235-40 (1998)
/	EE 19	" <i>In vitro</i> schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743)"; Ghielmini, M., et al, Annals of Oncology 9, pp. 989-93 (1998)

FEB 12 2003

Sheet 3 of 5

TECH CENTER 1600/2900

/	FF 20	"Differential toxicity of anticancer drugs on late (GM-CFC) and early (LTC-IC) hemopoietic progenitors <i>in vitro</i> "; Ghielmini, M., et al, Cell Biology and Toxicology 15, pp. 395-404 (1999)
/	GG 21	"Inhibition of CFU-E/BFU-E by 3'-Azido-3'-deoxythymidine, Chlorpropamide, and Protoporphirin IX Zinc (II): A Comparison between Direct Exposure of Progenitor Cells and Long-Term Exposure of Bone Marrow Cultures"; Gribaldo, L., et al, Toxicological Sciences 58, pp. 96-101 (2000)
/	HH 22	"Hemopoietic dynamics in grey collies"; Haurie, Caroline, et al, Experimental Hematology 27, pp. 1139-48 (1999)
/	II 23	"The Organization of Hemopoietic Tissue as Inferred from the Effects of 5-Fluorouracil"; Hodgson, G.S., Bradley, T.R. & Radley, J.M., Experimental Hematology, Vol. 10, No. 1, pp. 26-35 (1982)
/	JJ 24	"In Vitro Production of CFU-S and Cells with Erythropoiesis Repopulating Ability by 5-Fluorouracil Treated Mouse Bone Marrow"; Hodgson, G.S., Bradley, T.R. & Radley, J.M., International Journal of Cell Cloning 1, pp. 49-56 (1983)
/	KK 25	"Monoterpenes As Regulators Of Malignant Cell Proliferation"; Hohl, Raymond J., Adv. Exp. Med. Biol., Vol. 401, pp. 136-146 (1996)
/	LL 26	"The Myelotoxicity of chloramphenicol: <i>in vitro</i> and <i>in vivo</i> studies: I. <i>In vitro</i> effects on cells in culture"; Holt, D.E., et al, Hum. Exp. Toxicol., Vol. 16, pp. 570-576 (1997)
/	MM 27	"Colorimetric determination of inhibition of hematopoietic progenitor cells in soft agar"; Horowitz, D. & King, Andrew G., Journal of Immunological Methods 244, pp. 49-58 (2000)
/	NN 28	"Erythroid Colony Formation in Cultures of Mouse and Human Bone Marrow: Analysis of the Requirement for Erythropoietin by Gel Filtration and Affinity Chromatography on Agarose-Concanavalin A"; Iscove, N., Sieber, F. & Winterhalter, H., Journal of Cell. Physiology, 83, pp. 309-320 (1974)
/	OO 29	"A Miniaturized Agar Culture System for Cloning Human Erythropoietic Progenitor Cells"; Konwalinka, G., et al, Experimental Hematology, Vol. 12, pp. 75-79 (1984)
/	PP 30	"Use of the Microculture Kinetic Assay of Apoptosis to Determine Chemosensitivities of Leukemias"; Kravtsov, V.D., et al, Blood, Vol. 92, No. 3, pp. 968-980 (1998)
/	QQ 31	"Chrono Biological Aspects Of Bone Marrow And Blood Cells"; Laerum, O.D. & Aardal, N.P., 11 th Int'l Congress of Anatomy: Biological Rhythms in Structure and Function, pp. 87-97 (1981)
/	RR (32)	"Hematopoiesis occurs in rhythms"; Laerum, O.D., Experimental Hematology 23, pp. 1145-47 (1995)
/	SS 33	" <i>In Vitro</i> Toxicity of A 3'-Azido-3'-Deoxythymidine and Hydroxyurea Combination on Normal Myeloid Progenitors"; Lerza, R., et al, Anticancer Research 18, pp. 2755-58 (1998)
/	TT 34	"Improved Plasma Culture System for Production of Erythrocytic Colonies In Vitro: Quantitative Assay Method for CFU-E"; McLeod, D.L., et al, Blood, Vol. 44, No. 4, pp. 517-534 (1974)
/	UU 35	"Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays"; Mosman, Tim, Journal of Immunological Methods, Vol 65, pp. 55-63 (1983)

VV 36	"A sensitive sandwich ELISA for measuring erythropoietin in human serum"; Noe, G., et al, British Journal of Haematology, Vol. 80, pp. 285-292 (1992)
WW 37	"Roles for In Vitro Myelotoxicity Tests in Preclinical Drug Development and Clinical Trial Planning"; Parchment, R.E., et al, Toxicologic Pathology, Vol. 21, No. 2, pp. 241-50 (1993)
XX 38	"Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from <i>in vitro</i> tests"; Parchment, R.E., et al, Ann Oncol., Vol. 9, pp. 357-364 (1998)
YY 39	"In vitro Study of Pesticide Hematotoxicity in Human and Rat Progenitors"; Parent-Massin, D. & Thouvenot, D., Journal of Pharmacological and Toxicological Methods, Vol. 30, pp. 203-207 (1993)
ZZ 40	"Use of Limiting-Dilution Type Long-Term Marrow Cultures in Frequency Analysis of Marrow-Repopulating and Spleen Colony-forming Hematopoietic Stem Cells in the Mouse"; Ploemacher, R.E., et al, Blood, Vol. 78, No. 10, pp. 2527-2533 (1991)
AAA 41	"The Induction of Clones of Normal Mast Cells By A Substance From Conditioned Medium"; Pluznik, D.H. & Sachs, L., Experimental Cell Research, Vol. 43, pp. 553-63 (1966)
BBB 42	"The Effect of Stem Cell Proliferation Regulators Demonstrated With an <i>in vitro</i> Assay"; Pragnell, I.B., et al, Blood, Vol. 72, No. 1, pp. 196-201 (1988)
CCC 43	"ECVAM's in-house prevalidation/validation studies in the areas of haematotoxicity, reproductive toxicity, metabolism-mediated toxicity and epithelial barrier function"; Prieto, Pilar, The Sciences of the Total Environment, Vol. 247, pp. 349-354 (2000)
DDD 44	"The Effect of 5-Fluorouracil on Erythropoiesis"; Rich, Ivan, Blood, Vol. 77, No. 6, pp. 1164-70 (1991)
EEE 45	"The Developmental Biology of Hemopoiesis: Effect of Growth Factors on the Colony Formation by Embryonic Cells"; Rich, Ivan, Experimental Hematology, Vol. 20, pp. 368-70 (1992)
FFF 46	"Specific Enhancement of Mouse CFU-E by Mouse Transferrin"; Rich, Ivan, et al, British Journal of Haematology, Vol. 49, pp. 567-573 (1981)
GGG 47	"The effect of reduced oxygen tension on colony formation of erythropoietic cells <i>in vitro</i> "; Rich, Ivan, & Kubanek, B., British Journal of Haematology, Vol. 52, pp. 579-588 (1982)
HHH 48	"Haemopoietic stem cells are organized for use on the basis of their generation-age"; Rosendaal, M., et al, Nature, Vol. 264, pp. 68-69 (1976)
III 49	"Circadian Variation in Cell Division of the Mouse Alimentary Tract, Bone Marrow and Corneal Epithelium"; Scheving, L., et al, Anat. Rec., Vol. 191, pp. 479-486 (1978)
JJJ 50	"The Toxicology of Benzene"; Synder, Robert., et al, Environmental Health Perspectives, Vol. 100, pp. 293-306 (1993)
KKK 51	"What controls hair follicle cycling?"; Stenn, K.S., et al, Experimental Dermatology, Vol. 8, pp. 229-236 (1999) 236
LLL 52	"Distinct circadian time structures characterize myeloid and erythroid progenitor and multipotential cell clonogenicity as well as marrow precursor proliferation dynamics"; Wood, Patricia, et al, Experimental Hematology, Vol 26, pp. 523-533 (1998)

FEB 12 2003

Sheet 5 of 5

TECH CENTER 1600/2900

MMM 53	"Expression of the Circadian Clock Genes <i>clock</i> and <i>period1</i> in Human Skin"; Zanello, Susana, et al, Journal of Invest Dermatol., Vol. 115, pp. 757-760 (2000)
NNN 54	"The sensitivity of in vitro erythropoietic progenitor cells to different erythropoietin reagents during development and the role of cell death in culture"; Zimmerman, Frank & Rich, Ivan, Experimental Hematology, Vol. 24, pp. 330-39 (1996)